Plain-English translation of NCT05443178 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers are testing whether chloroquine (a medication normally used for malaria) can be safely added to standard tuberculosis treatment to make it work better. Early laboratory studies suggest that chloroquine may help tuberculosis medications get inside infected cells more effectively, potentially shortening treatment time and improving cure rates. This is the first study in humans to check if this combination is safe.
Tuberculosis remains a major cause of death worldwide, and current treatments are long and sometimes difficult to tolerate. Researchers believe this medication could boost the power of existing tuberculosis drugs and make treatment faster and more bearable, but they need to first confirm it's safe when taken together with standard therapy.
You likely qualify if…
You likely don't qualify if…
You would take both medications by mouth once daily for 14 days. The study starts with the lowest dose of the added medication, and depending on how safe and well-tolerated it is, later groups may receive higher doses. You'll need to attend visits for blood tests and checkups, and you'll be monitored for any side effects. The study includes a follow-up period lasting several months to make sure you remain healthy after stopping the medications.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Switzerland
Phase
Safety & dosing
Sponsor
University of Zurich
Enrollment target
~16 participants
Started
January 2022
Primary completion
October 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 50 Years
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Khadija M'Rabet, Dr. med.
University of Zurich
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.